Information  X 
Enter a valid email address

Verona Pharma PLC Ord 5P (VRP)

Related News

14-Aug-2020 08:58 AM

Verona Pharma to start Covid-19 treatment trial later in 2020

Respiratory diseases focused Verona Pharma posted a second-quarter loss on the back of R&D spending and said it planned to start a clinical trial of patients hosptilized with Covid-19 by the end of 2020. Pre-tax losses for the three months through June a
30-Apr-2020 10:00 AM

Broker Forecast - Shore Capital issues a broker note on Verona Pharma PLC

Shore Capital today downgrades its investment rating on Verona Pharma PLC (LON:VRP) to hold (from buy). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
05-Nov-2019 09:45 AM

Verona Pharma losses deepen on higher R&D spend

Respiratory disease focused Verona Pharma booked a deeper third-quarter loss after it ramped up R&D spending. Pre-tax losses for the three months through September amounted to £12.8m, compared to losses of £3.5m on-year. The company is devel
06-Aug-2019 09:17 AM

Verona Pharma books first-half loss amid higher R&D spend

Respiratory disease focused Verona Pharma booked a first-half loss, as it ramped up research and development spending. Pre-tax losses for the six months through June amounted to £17.8m, compared to losses of £16.5m on-year. R&D costs rose to
07-Aug-2018 09:30 AM

Verona Pharma losses deepen as finance costs rise

Respiratory diseases-focused Verona Pharma said it booked an £11.5m operating loss for the six months through June as it continued to invest in a treatment for chronic obstructive pulmonary disease. The loss had widened from £10.9m of red ink
08-May-2018 10:50 AM

Broker Forecast - Shore Capital issues a broker note on Verona Pharma PLC

Shore Capital today reaffirms its buy investment rating on Verona Pharma PLC (LON:VRP) and cut its price target to 160p (from 173p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
11-Apr-2018 11:10 AM

Broker Forecast - Shore Capital issues a broker note on Verona Pharma PLC

Shore Capital today initiates coverage of Verona Pharma PLC (LON:VRP) with a buy investment rating and price target of 173p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
21-Mar-2018 01:10 PM

Broker Forecast - N+1 Singer issues a broker note on Verona Pharma PLC

N+1 Singer today reaffirms its strong buy investment rating on Verona Pharma PLC (LON:VRP) and raised its price target to 348p (from 327p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
27-Nov-2017 11:40 AM

Broker Forecast - N+1 Singer issues a broker note on Verona Pharma PLC

N+1 Singer today reaffirms its buy investment rating on Verona Pharma PLC (LON:VRP) and set its price target at 327p. Story provided by StockMarketWire.com...
07-Nov-2017 09:15 AM

Verona Pharma losses deepen

Verona Pharma said its third-quarter losses more than tripled after research and development costs rose. The company booked a net loss for the three months through September of £9.1m, extending a £2.5m loss reported a year earlier. R&D cost
19-Sep-2017 01:05 PM

Verona to issue shares

Verona Pharma has announced that it will issue 133,333 new ordinary shares following an exercise of share options by N+1 Singer Capital Markets Limited. At 1:05pm: (LON:VRP) Verona Pharma PLC share price was 0p at 147.5p Story provided by StockMark
08-Aug-2017 09:57 AM

Verona Pharma losses widen as it starts clinical trials

Verona Pharma (VRP), a clinical-stage biopharmaceutical company, made a loss after tax of £5.1 million in the first half, compared with a loss of £1.8 million the year before. The company said this reflected the preparation and initiation of
01-Aug-2017 03:00 PM

Verona to present at healthcare conference

Verona Pharma has confirmed that Jan-Anders Karlsson, PhD, CEO of the Company, is scheduled to present at the 2017 Wedbush PacGrow Healthcare Conference on 15 August. At 3:00pm: (LON:VRP) Verona Pharma PLC share price was 0p at 116.5p Story provid
23-May-2017 01:34 PM

Verona CEO to present at Jefferies Healthcare Conference

Verona Pharma has confirmed that Jan-Anders Karlsson, PhD, CEO of the Company, is scheduled to present at the Jefferies 2017 Global Healthcare Conference. At 1:34pm: (LON:VRP) Verona Pharma PLC share price was +7.5p at 146.5p Story provided by StockMa
22-May-2017 09:10 AM

Broker Forecast - Jefferies International issues a broker note on Verona Pharma PLC

Jefferies International today initiates coverage of Verona Pharma PLC (LON:VRP) with a buy investment rating and price target of 250p. Story provided by StockMarketWire.com...
12-Apr-2017 01:21 PM

All resolutions passed at Verona AGM

Verona Pharma has confirmed that all resolutions proposed at the Annual General Meeting (AGM) held today were duly passed. At 1:21pm: (LON:VRP) Verona Pharma PLC share price was 0p at 136p Story provided by StockMarketWire.com...
20-Mar-2017 02:00 PM

Verona Pharma schedules AGM

Verona Pharma has confirmed that the Annual General Meeting of the Company will be held on 12th April 2017. At 2:00pm: (LON:VRP) Verona Pharma PLC share price was -1p at 140.5p Story provided by StockMarketWire.com...
27-Feb-2017 09:45 AM

Verona Pharma narrows FY pretax loss

Verona Pharma has narrowed its FY pretax loss to £5.97m, from a year-ago restated loss of £9.0m. Most of the losses were linked to R&D and general & administrative costs. At 9:45am: (LON:VRP) Verona Pharma PLC share price was +10.5p at 141
08-Feb-2017 01:35 PM

Verona share consolidation approved by shareholders

Verona Pharma has announced that all resolutions proposed at the General Meeting held earlier today were duly passed. Accordingly, the share capital of the Company will be consolidated. Every 50 existing Ordinary Shares, each with a nominal value of &po
27-May-2016 02:57 PM

Verona Pharma schedules FY results

Verona Pharma - the drug development company focused on first-in-class medicines to treat respiratory diseases - expects to announce its preliminary results for the year ended 31 December on 3 June. At 2:57pm: (LON:VRP) Verona Pharma PLC share price was
21-Mar-2016 11:30 AM

Verona expects pre-tax losses to rise to GBP8.9m

Verona Pharma says it expects to report a pre-tax loss of approximately GBP8.9m for the year ended 31 December 2015 (2014:GBP2.8m), broadly in line with market expectations, reflecting tight cost control despite the planned increase in R&D spend, especial
12-May-2015 07:21 AM

Verona's FY loss

Verona Pharma has widened its FY pretax loss to £3.8m, from a loss of £2.8m. Revenue was nil. Highlights: * Developed a novel commercial formulation for lead compound RPL554 (a first-in-class, dual PDE3/PDE4 inhibitor with both bronchodilator and an
03-Mar-2015 07:44 AM

VRP sees slightly lower than expected FY pretax loss

Verona Pharma expects to report a slightly lower than expected loss before tax of about £3.7m for the year to Dec. 31, 2014. The loss reflects slightly lower than expected expenditure on R&D and slightly lower expenditure than expected on general and adm
11-Sep-2014 08:00 AM

Verona Pharma financed to support further development

Verona Pharma (AIM: VRP), the drug development company focused on first-in-class medicines to treat respiratory diseases, has announced its interim results for the six months ended 30 June 2014 which show a loss after tax for the period of £1.40m (2013:
28-Apr-2014 07:57 AM

Verona Pharma FY pretax loss widens to £2.8m

Verona Pharma said its FY pretax loss widened to £2.8m, from a loss of £2.6m. Revenue was nil. CEO Jan-Anders Karlsson said during the year Verona continued to implement its strategy of creating a biopharmaceutical company focused on addressing large m
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t